|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:approvalYear
|
1996
|
|
gptkbp:ATCCode
|
gptkb:C10AA05
|
|
gptkbp:bioavailability
|
14%
|
|
gptkbp:blackBoxWarning
|
false
|
|
gptkbp:CASNumber
|
134523-00-5
|
|
gptkbp:chemicalClass
|
gptkb:pyrrole
heptanoic acid derivative
|
|
gptkbp:contraindication
|
pregnancy
breastfeeding
active liver disease
|
|
gptkbp:drugClass
|
statin
|
|
gptkbp:drugInteraction
|
gptkb:fibrates
gptkb:digoxin
niacin
CYP3A4 inhibitors
oral contraceptives
|
|
gptkbp:eliminatedIn
|
biliary
renal (minor)
|
|
gptkbp:eliminationHalfLife
|
14 hours
|
|
gptkbp:hasInChIKey
|
XUKUURHRXDUEBC-KAYWLYCHSA-N
|
|
gptkbp:hasLogP
|
6.36
|
|
gptkbp:hasMolecularFormula
|
C33H35FN2O5
|
|
gptkbp:hasSMILES
|
CC(C)C1=CC=C(C=C1)C(C(=O)O)N(C)C2=CC(=C(C=C2)F)C3=CC=CC=C3C(=O)O
|
|
gptkbp:hasUNII
|
83HN0GTJ6D
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
CHEMBL511
|
|
gptkbp:indication
|
gptkb:familial_hypercholesterolemia
prevention of cardiovascular disease
|
|
gptkbp:isApprovedDrug
|
true
|
|
gptkbp:legalStatus
|
expired
prescription only
|
|
gptkbp:manufacturer
|
gptkb:Pfizer
|
|
gptkbp:mechanismOfAction
|
HMG-CoA reductase inhibitor
|
|
gptkbp:meltingPoint
|
159-160°C
|
|
gptkbp:metabolism
|
gptkb:CYP3A4
|
|
gptkbp:molecularWeight
|
558.7
|
|
gptkbp:name
|
gptkb:atorvastatin
|
|
gptkbp:pregnancyCategory
|
gptkb:X_(US)
|
|
gptkbp:proteinBinding
|
98%
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL511
60823
DB01076
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
liver enzyme abnormalities
muscular dystrophy
rhabdomyolysis
|
|
gptkbp:synonym
|
gptkb:Lipitor
Atorvastatin calcium
Sortis
Torvast
|
|
gptkbp:target
|
gptkb:HMGCR
|
|
gptkbp:toxicity
|
overdose may cause severe myopathy
|
|
gptkbp:bfsParent
|
gptkb:basic_blue_9
|
|
gptkbp:bfsLayer
|
7
|